Related Experiment Video
Updated: Jan 6, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
The P4HA1/HIF1α feedback loop modulates endothelial dysfunction in pulmonary hypertension
Yunwei Chen1, Yifei Lv1, Meng Yang1
1Division of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
The glycolytic protein P4HA1 is upregulated in pulmonary hypertension (PH). Targeting the P4HA1/HIF1α pathway may offer a new therapeutic strategy for treating PH and its associated vascular remodeling.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Cellular Metabolism
Background:
- Pulmonary hypertension (PH) is a severe vascular disease leading to right heart failure.
- The role of the glycolytic protein P4HA1 in PH pathogenesis is not well understood.
Purpose of the Study:
- To investigate the role of P4HA1 in the pathogenesis of pulmonary hypertension.
- To elucidate the P4HA1/HIF1α signaling axis in hypoxia-induced pulmonary vascular remodeling.
Main Methods:
- RNA-sequencing of hypoxic human pulmonary artery endothelial cells (HPAECs).
- In vitro knockdown of P4HA1 to assess effects on glycolysis, proliferation, and migration.
- Mechanistic studies on HIF1α regulation and P4HA1-mediated stabilization.
- In vivo assessment using AAV9-shP4HA1 in a mouse PH model.
Main Results:
- P4HA1 is upregulated in HPAECs under hypoxia, transcriptionally activated by HIF1α.
- P4HA1 stabilizes HIF1α, creating a self-amplifying loop.
- P4HA1 knockdown suppressed hypoxia-induced glycolysis, proliferation, and migration in HPAECs.
- Endothelial-specific P4HA1 knockdown attenuated pulmonary vascular remodeling and improved right ventricular function in vivo.
Conclusions:
- P4HA1 is a novel contributor to PH pathogenesis.
- Targeting the P4HA1/HIF1α axis presents a potential therapeutic strategy for pulmonary hypertension.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Heart Failure II: Pathophysiology
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

